Korea South
Deargen, founded in 2016, positions itself as a pioneer in the intersection of AI and pharmaceuticals. This AI-First Pharmatech Company focuses on revolutionizing drug discovery and development through sequence-based AI solutions. Headquartered in Korea South, the company leverages advanced AI, particularly transformer technology, to overcome traditional challenges in drug research, such as the dependency on 3D protein structures.
Their innovative approach positions them as a potential game-changer in the AI, Biotechnology, and Machine Learning industries. A standout feature of Deargen is its end-to-end AI platform that accelerates drug discovery while cutting costs, making it attractive for investors seeking impactful ventures.
In their latest funding round, Deargen secured a KRW20.00B Series B investment on February 24, 2022, with backing from prominent investors such as Korea Development Bank, TS Investment, Hana Ventures, The Wells Investment, Inc., and Nvestor (Korea). This financial support highlights significant confidence in their innovative potential and market readiness.
--logo.jpg "Wellmarker Bio (WMBIO)"){kind=logo}